Pharmacogenetic Approaches in the Treatment of Asthma

Overview

Journal Curr Allergy Asthma Rep

Specialties Allergy & Immunology
Pulmonary Medicine

Date 2005 Feb 3

PMID 15683609

Citations 13

Authors

Ian Sayers

Ian P Hall

Affiliations

Soon will be listed here.

Abstract

A patient's response to asthma therapy is determined by both genetic and environmental factors. In the past 10 years, we have witnessed significant progress in the field of asthma pharmacogenetics--the study of how a patient's genetic background determines the efficacy and potential for adverse effects to current asthma medication. There are now clear examples of gene polymorphisms that can influence responses to beta(2)-agonists, glucocorticosteroids, and leukotriene modifier drugs, the three main classes of medication used clinically to treat asthma. Identification of genetic polymorphism that predicts drug responses has the potential to lead to the development of new therapeutics, improve asthma management, and reduce serious episodes and hospitalizations. In this review, we discuss the current understanding of asthma pharmacogenetics, focusing on the main three classes of drugs currently used clinically.

Citing Articles

Pharmacogenomics of Leukotriene Modifiers: A Systematic Review and Meta-Analysis.

Zhao Y, Zhang X, Han C, Cai Y, Li S, Hu X J Pers Med. 2022; 12(7).

PMID: 35887565 PMC: 9316609. DOI: 10.3390/jpm12071068.

Oxidative Stress and Antioxidant Pathway in Allergic Rhinitis.

Han M, Lee D, Lee S, Kim T Antioxidants (Basel). 2021; 10(8).

PMID: 34439514 PMC: 8389336. DOI: 10.3390/antiox10081266.

Oxidative stress and cellular pathways of asthma and inflammation: Therapeutic strategies and pharmacological targets.

Mishra V, Banga J, Silveyra P Pharmacol Ther. 2017; 181:169-182.

PMID: 28842273 PMC: 5743757. DOI: 10.1016/j.pharmthera.2017.08.011.

Physicians' pharmacogenomics information needs and seeking behavior: a study with case vignettes.

Heale B, Khalifa A, Stone B, Nelson S, Del Fiol G BMC Med Inform Decis Mak. 2017; 17(1):113.

PMID: 28764766 PMC: 5540399. DOI: 10.1186/s12911-017-0510-9.

Defining the inflammatory signature of human lung explant tissue in the presence and absence of glucocorticoid.

Rimington T, Hodge E, Billington C, Bhaker S, K C B, Kilty I F1000Res. 2017; 6:460.

PMID: 28721202 PMC: 5497818. DOI: 10.12688/f1000research.10961.1.

References

Parola A, Kobilka B . The peptide product of a 5' leader cistron in the beta 2 adrenergic receptor mRNA inhibits receptor synthesis. J Biol Chem. 1994; 269(6):4497-505. View

Currie G, Lima J, Sylvester J, Lee D, Cockburn W, Lipworth B . Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma. Br J Clin Pharmacol. 2003; 56(4):422-6. PMC: 1884371. DOI: 10.1046/j.1365-2125.2003.01952.x. View

Fenech A, Hall I . Pharmacogenetics of asthma. Br J Clin Pharmacol. 2002; 53(1):3-15. PMC: 1874556. DOI: 10.1046/j.0306-5251.2001.01509.x. View

Hancox R, Sears M, Taylor D . Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. Eur Respir J. 1998; 11(3):589-93. View

Tantisira K, Lake S, Silverman E, Palmer L, Lazarus R, Silverman E . Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet. 2004; 13(13):1353-9. DOI: 10.1093/hmg/ddh149. View

Lee D, Currie G, Hall I, Lima J, Lipworth B . The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol. 2003; 57(1):68-75. PMC: 1884417. DOI: 10.1046/j.1365-2125.2003.01955.x. View

Koyano S, Saito Y, Nagano M, Maekawa K, Kikuchi Y, Murayama N . Functional analysis of three genetic polymorphisms in the glucocorticoid receptor gene. J Pharmacol Exp Ther. 2003; 307(1):110-6. DOI: 10.1124/jpet.103.054155. View

Green S, Cole G, Jacinto M, Innis M, Liggett S . A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem. 1993; 268(31):23116-21. View

Tan S, Hall I, Dewar J, Dow E, Lipworth B . Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet. 1997; 350(9083):995-9. DOI: 10.1016/S0140-6736(97)03211-X. View

10.

Fenech A, Ebejer M, Felice A, Ellul-Micallef R, Hall I . Mutation screening of the muscarinic M(2) and M(3) receptor genes in normal and asthmatic subjects. Br J Pharmacol. 2001; 133(1):43-8. PMC: 1572756. DOI: 10.1038/sj.bjp.0704039. View

11.

Lipworth B, Koppelman G, P Wheatley A, Le Jeune I, Coutie W, Meurs H . Beta2 adrenoceptor promoter polymorphisms: extended haplotypes and functional effects in peripheral blood mononuclear cells. Thorax. 2002; 57(1):61-6. PMC: 1746184. DOI: 10.1136/thorax.57.1.61. View

12.

Malchoff D, Brufsky A, Reardon G, McDermott P, Javier E, Bergh C . A mutation of the glucocorticoid receptor in primary cortisol resistance. J Clin Invest. 1993; 91(5):1918-25. PMC: 288186. DOI: 10.1172/JCI116410. View

13.

Drysdale C, McGraw D, Stack C, Stephens J, Judson R, Nandabalan K . Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A. 2000; 97(19):10483-8. PMC: 27050. DOI: 10.1073/pnas.97.19.10483. View

14.

Sampson A, Cowburn A, Sladek K, Adamek L, Nizankowska E, Szczeklik A . Profound overexpression of leukotriene C4 synthase in bronchial biopsies from aspirin-intolerant asthmatic patients. Int Arch Allergy Immunol. 1997; 113(1-3):355-7. DOI: 10.1159/000237600. View

15.

Mastalerz L, Nizankowska E, Sanak M, Mejza F, Pierzchalska M, Bazan-Socha S . Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest. 2003; 32(12):949-55. DOI: 10.1046/j.1365-2362.2002.01088.x. View

16.

Johnatty S, Abdellatif M, Shimmin L, Clark R, Boerwinkle E . Beta 2 adrenergic receptor 5' haplotypes influence promoter activity. Br J Pharmacol. 2002; 137(8):1213-6. PMC: 1573596. DOI: 10.1038/sj.bjp.0704935. View

17.

Green S, Turki J, Innis M, Liggett S . Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994; 33(32):9414-9. DOI: 10.1021/bi00198a006. View

18.

Taylor D, Drazen J, Herbison G, Yandava C, Hancox R, Town G . Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax. 2000; 55(9):762-7. PMC: 1745862. DOI: 10.1136/thorax.55.9.762. View

19.

Choi J, Park H, Oh H, Lee J, Suh Y, Park C . Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase. Hum Genet. 2004; 114(4):337-44. DOI: 10.1007/s00439-004-1082-1. View

20.

Drazen J, Yandava C, Dube L, Szczerback N, Hippensteel R, Pillari A . Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999; 22(2):168-70. DOI: 10.1038/9680. View